$AURX
Nuo Therapeutics Inc Stock $aurx

$aurx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000143774917014570 Filed on August 14, 2017

Income Statement

Concept	2017 Q2	2016 Q2
Revenue	$188.6K	$134.9K
YoY Change	39.85%	-95.34%
Cost Of Revenue	$277.4K	$175.8K
YoY Change	57.76%	-92.62%
Gross Profit	-$88.77K	-$40.96K
YoY Change	116.75%	-107.98%
Gross Profit Margin	-47.07%	-30.37%
Selling, General & Admin	$1.433M	$840.1K
YoY Change	70.6%	-80.7%
% of Gross Profit
Research & Development	$309.5K	$224.4K
YoY Change	37.94%	-62.47%
% of Gross Profit
Depreciation & Amortization	$81.00K	$209.0K
YoY Change	-61.24%	16.11%
% of Gross Profit
Operating Expenses	$3.822M	$1.065M
YoY Change	259.05%	-78.5%
Operating Profit	-$3.911M	-$1.105M
YoY Change	253.77%	-75.09%
Interest Expense	-$1.259K	-$109.00
YoY Change	1055.05%	-99.99%
% of Operating Profit
Other Income/Expense, Net	-$1.240K	-$189.4K
YoY Change	-99.35%	-105.3%
Pretax Income	-$3.910M	-$1.295M
YoY Change	201.97%	49.63%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.912M	-$1.295M
YoY Change	202.13%	48.79%
Net Earnings / Revenue	-2074.26%	-960.16%
Basic Earnings Per Share	-$0.39	$0.17
Diluted Earnings Per Share	-$0.39	-$0.13
COMMON SHARES
Basic Shares Outstanding	9.927M	9.794M
Diluted Shares Outstanding	9.927M	9.794M

Balance Sheet

Concept	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$330.0K	$6.070M
YoY Change	-94.56%	-11.9%
Cash & Equivalents	$331.0K	$10.36M
Short-Term Investments
Other Short-Term Assets	$330.0K	$750.0K
YoY Change	-56.0%	-75.33%
Inventory	$89.18K	$56.35K
Prepaid Expenses
Receivables	$150.0K	$1.230M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$900.0K	$12.35M
YoY Change	-92.71%	-3.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$307.1K	$865.7K
YoY Change	-64.53%	-0.95%
Goodwill	$0.00	$2.100M
YoY Change	-100.0%	86.08%
Intangibles	$7.414M	$8.400M
YoY Change	-11.73%	-70.62%
Long-Term Investments
YoY Change
Other Assets	$218.3K	$340.0K
YoY Change	-35.79%	-88.83%
Total Long-Term Assets	$7.940M	$11.70M
YoY Change	-32.13%	-65.23%
TOTAL ASSETS
Total Short-Term Assets	$900.0K	$12.35M
Total Long-Term Assets	$7.940M	$11.70M
Total Assets	$8.840M	$24.05M
YoY Change	-63.24%	-48.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$645.0K	$2.877M
YoY Change	-77.58%	65.53%
Accrued Expenses	$1.205M	$3.112M
YoY Change	-61.28%	-45.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$1.850M	$5.989M
YoY Change	-69.11%	-23.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$80.34K	$171.6K
YoY Change	-53.18%	-65.49%
Total Long-Term Liabilities	$80.34K	$171.6K
YoY Change	-53.18%	-65.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.850M	$5.989M
Total Long-Term Liabilities	$80.34K	$171.6K
Total Liabilities	$1.930M	$2.789M
YoY Change	-30.79%	-89.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.30M	$0.00
YoY Change		-100.0%
Common Stock	$993.00	$993.00
YoY Change	0.0%	-92.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.909M	$17.89M
YoY Change
Total Liabilities & Shareholders Equity	$8.840M	$24.05M
YoY Change	-63.24%	-48.24%

Cashflow Statement

Concept	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$3.912M	-$1.295M
YoY Change	202.13%	48.79%
Depreciation, Depletion And Amortization	$81.00K	$209.0K
YoY Change	-61.24%	16.11%
Cash From Operating Activities	-$1.010M	-$4.830M
YoY Change	-79.09%	-2.62%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.20M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-1.010M	-4.830M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	0.000	10.20M
Net Change In Cash	-1.010M	5.370M
YoY Change	-118.81%	-208.92%
FREE CASH FLOW
Cash From Operating Activities	-$1.010M	-$4.830M
Capital Expenditures		$0.00
Free Cash Flow		-$4.830M
YoY Change		-2.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q2	nuot	Authorized Shares Common And Preferred AuthorizedSharesCommonAndPreferred	32500000
CY2016Q2	nuot	Debt Free Net Cash Flow Growth Rate DebtFreeNetCashFlowGrowthRate	0.034
CY2016Q4	nuot	Debt Instrument Number Of Periodic Payments DebtInstrumentNumberOfPeriodicPayments	3
	nuot	Debt Issuance Costs On Short Term Debtor In Posession Note Payable DebtIssuanceCostsOnShortTermDebtorInPosessionNotePayable
CY2016Q2	nuot	Debt Issuance Costs On Short Term Debtor In Posession Note Payable DebtIssuanceCostsOnShortTermDebtorInPosessionNotePayable
CY2016Q2	nuot	Debtor Reorganization Items Gain Loss On Reorganization Adjustments Net DebtorReorganizationItemsGainLossOnReorganizationAdjustmentsNet
CY2017Q2	nuot	Direct Operating Cost Royalty Expense Recovery DirectOperatingCostRoyaltyExpenseRecovery
CY2016Q2	nuot	Direct Operating Cost Royalty Expense Recovery DirectOperatingCostRoyaltyExpenseRecovery
	nuot	Direct Operating Cost Royalty Expense Recovery DirectOperatingCostRoyaltyExpenseRecovery
CY2016Q2	nuot	Fresh Start Accounting Percent Of Voting Share Of Emerging Entity FreshStartAccountingPercentOfVotingShareOfEmergingEntity	0.5
CY2016Q2	nuot	Fresh Start Adjustment Increase Decrease Common And Preferred Stock At Par FreshStartAdjustmentIncreaseDecreaseCommonAndPreferredStockAtPar	-753
CY2016Q2	nuot	Freshstart Adjustment Increase Decrease Common Stock Issuable FreshstartAdjustmentIncreaseDecreaseCommonStockIssuable	-392950
CY2016Q2	nuot	Freshstart Adjustment Increase Decrease Intangible Assets Including Goodwill FreshstartAdjustmentIncreaseDecreaseIntangibleAssetsIncludingGoodwill	10476284
	nuot	Noncash Gain Loss On Reorganisation NoncashGainLossOnReorganisation
CY2016Q2	nuot	Noncash Gain Loss On Reorganisation NoncashGainLossOnReorganisation
CY2016Q2	nuot	Payment For Offering Cost PaymentForOfferingCost	100000
CY2016Q2	nuot	Payments For Reorganization Items PaymentsForReorganizationItems	1054426
CY2017Q2	nuot	Percentage Of Revenues Generated Outside Of United States PercentageOfRevenuesGeneratedOutsideOfUnitedStates	0.22
CY2016Q2	nuot	Percentage Of Revenues Generated Outside Of United States PercentageOfRevenuesGeneratedOutsideOfUnitedStates	0.1
	nuot	Percentage Of Revenues Generated Outside Of United States PercentageOfRevenuesGeneratedOutsideOfUnitedStates	0.28
	nuot	Percentage Of Revenues Generated Outside Of United States PercentageOfRevenuesGeneratedOutsideOfUnitedStates	0.11
CY2016Q2	nuot	Post Confirmation Tangible Assets PostConfirmationTangibleAssets	13574000
CY2016Q2	nuot	Post Confirmation Tangible Assets PostConfirmationTangibleAssets	13574000
CY2016Q2	nuot	Postconfirmation Common Stock Issuable PostconfirmationCommonStockIssuable
CY2016Q2	nuot	Postconfirmation Conditionally Redeemable Common Stock PostconfirmationConditionallyRedeemableCommonStock
CY2016Q2	nuot	Postconfirmation Deferred Costs And Other Assets Noncurrent PostconfirmationDeferredCostsAndOtherAssetsNoncurrent	355741
CY2016Q2	nuot	Preconfirmation Common Stock Issuable PreconfirmationCommonStockIssuable	392950
CY2016Q2	nuot	Preconfirmation Conditionally Redeemable Common Stock PreconfirmationConditionallyRedeemableCommonStock	500000
CY2016Q2	nuot	Preconfirmation Deferred Costs And Other Assets Noncurrent PreconfirmationDeferredCostsAndOtherAssetsNoncurrent	355741
	nuot	Preferred Stock Issued PreferredStockIssued
CY2016Q2	nuot	Preferred Stock Issued PreferredStockIssued	8288719
	nuot	Proceeds From Issuance Of Commonstock And Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonstockAndPreferredStockNetOfIssuanceCosts
CY2016Q2	nuot	Proceeds From Issuance Of Commonstock And Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonstockAndPreferredStockNetOfIssuanceCosts
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Additional Paidin Capital ReorganizationAdjustmentIncreaseDecreaseAdditionalPaidinCapital	-126011808
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Assets ReorganizationAdjustmentIncreaseDecreaseAssets	-2422510
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Common Stock ReorganizationAdjustmentIncreaseDecreaseCommonStock	-12477
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Conditionally Redeemable Common Stock ReorganizationAdjustmentIncreaseDecreaseConditionallyRedeemableCommonStock	-500000
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Current Assets ReorganizationAdjustmentIncreaseDecreaseCurrentAssets	-16053
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Deferred Revenue Current Portion ReorganizationAdjustmentIncreaseDecreaseDeferredRevenueCurrentPortion	-899920
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Elimination Of Various Payables And Accruals ReorganizationAdjustmentIncreaseDecreaseEliminationOfVariousPayablesAndAccruals	-773756
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Equity Excluding Retained Earnings ReorganizationAdjustmentIncreaseDecreaseEquityExcludingRetainedEarnings	-126917235
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Intangible Assets Net Excluding Goodwill ReorganizationAdjustmentIncreaseDecreaseIntangibleAssetsNetExcludingGoodwill	-2406457
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Liabilities ReorganizationAdjustmentIncreaseDecreaseLiabilities	-45739797
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Liabilities And Stockholders Equity ReorganizationAdjustmentIncreaseDecreaseLiabilitiesAndStockholdersEquity	-2422510
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Liabilities Subject To Compromise ReorganizationAdjustmentIncreaseDecreaseLiabilitiesSubjectToCompromise	-39089877
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Prepaid And Other Current Assets ReorganizationAdjustmentIncreaseDecreasePrepaidAndOtherCurrentAssets	-16053
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Retained Earnings Deficit ReorganizationAdjustmentIncreaseDecreaseRetainedEarningsDeficit	170234522
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Stockholders Equity ReorganizationAdjustmentIncreaseDecreaseStockholdersEquity	43817287
CY2016Q2	nuot	Reorganization Adjustment Increase Decrease Termination Of Debt Agreements And Accrued Interest ReorganizationAdjustmentIncreaseDecreaseTerminationOfDebtAgreementsAndAccruedInterest	-44066121
CY2017Q2	nuot	Time Deposits Annual Interest Rate TimeDepositsAnnualInterestRate	0.001
CY2017Q2	nuot	Time Deposits Interest Rate Renewal Term TimeDepositsInterestRateRenewalTerm	P240D
CY2016Q2	nuot	Warrant Expiration Date WarrantExpirationDate	2016-11-05
CY2017Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	153507
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	294298
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	644968
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	392615
CY2017Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	562418
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1205118
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1054677
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	455762
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	279601
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18208629
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18180658
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	409000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	409000
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	408911
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-466
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1228750
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6180000
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6180000
CY2017Q2	us-gaap	Assets Assets	8839766
CY2016Q4	us-gaap	Assets Assets	14056753
CY2017Q2	us-gaap	Assets Current AssetsCurrent	899985
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3372215
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	331034
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2620023
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10358209
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6066991
	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2288989
CY2016Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4291218
CY2017Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2017Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	81000
CY2016Q2	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2021-05-05
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	31500000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	31500000
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9927112
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9927112
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9927112
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9927112
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	993
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	993
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 15pt 0pt 18pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Credit Concentration</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">We generate accounts receivable from the sale of our products. In addition, other receivables consist primarily of the receivable due from our contract manufacturer for the cost of raw materials required to manufacture the Angel products that are purchased by the Company and immediately resold, at cost, to the contract manufacturer and a refund due for Delaware franchise taxes. Specific customer<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> or other receivables balances in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total receivables at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016 </div>were as follows:</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 15%; margin-left: 54pt;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 58%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 58%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">, 2017</div></div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt 0pt 0pt 18pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 58%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivable A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">58%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 58%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 18pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Revenue from significant customers exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of total revenues for the periods presented was as follows:</div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 36pt;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Predecessor</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30, 2017</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from May 5, 2016</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">through June 30, 2016</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from April 1, 2016</div></div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">through May 4, 2016</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer D</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer E</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer F</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt;"> </div> <div> <table style="; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-right: 10%; margin-left: 36pt;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Successor</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Predecessor</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six months ended</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30, 2017</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from May 5, 2016</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">through June 30, 2016</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="width: 1%; text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); padding: 0px;" nowrap="nowrap"> <div style=" margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Period from January 1, 2016<br /> through May 4, 2016</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 39%; font-family: "Times New Roman",Times,serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Customer D</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 18%; text-align: center; font-family: "Times New Roman",Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Historically, we used single suppliers for several components of the Aurix product line. We outsource the manufacturing of various products to contract manufacturers. While we believe these manufacturers demonstrate competency, reliability and stability, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of them will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.</div></div></div></div></div></div></div></div></div>
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	277371
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	175813
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	547458
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	277371
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	175813
	us-gaap	Cost Of Revenue CostOfRevenue	547458
CY2016Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	33333
CY2017Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	0
CY2016Q2	us-gaap	Debtor Reorganization Items Legal And Advisory Professional Fees DebtorReorganizationItemsLegalAndAdvisoryProfessionalFees	209402
CY2017Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	81000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	178000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	604347
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	208999
	us-gaap	Dilutive Securities DilutiveSecurities
CY2016Q2	us-gaap	Dilutive Securities DilutiveSecurities
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016Q2	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.29
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	982625
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	556592
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3580000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	426000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	852000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	852000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	852000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	852000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8397000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8397000
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7414375
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7840408
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Additional Paid In Capital FreshStartAdjustmentIncreaseDecreaseAdditionalPaidInCapital	17887966
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Amortizable Intangible Assets FreshStartAdjustmentIncreaseDecreaseAmortizableIntangibleAssets	8397000
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Assets FreshStartAdjustmentIncreaseDecreaseAssets	17528784
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Cash And Cash Equivalents FreshStartAdjustmentIncreaseDecreaseCashAndCashEquivalents	7052500
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Common Stock FreshStartAdjustmentIncreaseDecreaseCommonStock	750
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Current Assets FreshStartAdjustmentIncreaseDecreaseCurrentAssets	7052500
CY2016Q4	us-gaap	Fresh Start Adjustment Increase Decrease Goodwill FreshStartAdjustmentIncreaseDecreaseGoodwill	2079284
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Goodwill FreshStartAdjustmentIncreaseDecreaseGoodwill	2079284
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Liabilities And Stockholders Equity FreshStartAdjustmentIncreaseDecreaseLiabilitiesAndStockholdersEquity	17528784
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Preferred Stock FreshStartAdjustmentIncreaseDecreasePreferredStock	3
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Retained Earnings Deficit FreshStartAdjustmentIncreaseDecreaseRetainedEarningsDeficit	-359935
CY2016Q2	us-gaap	Fresh Start Adjustment Increase Decrease Stockholders Equity FreshStartAdjustmentIncreaseDecreaseStockholdersEquity	17528784
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1205
CY2016Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1272599
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	602817
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2247012
CY2016Q2	us-gaap	Goodwill Goodwill	2100000
CY2017Q2	us-gaap	Goodwill Goodwill	0
CY2015Q4	us-gaap	Goodwill Goodwill	0
CY2016Q4	us-gaap	Goodwill Goodwill	2079284
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2079284
CY2017Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2079284
CY2016Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss
CY2017Q2	us-gaap	Gross Profit GrossProfit	-88771
CY2016Q2	us-gaap	Gross Profit GrossProfit	-40956
	us-gaap	Gross Profit GrossProfit	-186115
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-141257
CY2016Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-60926
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	252353
CY2016Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1606527
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	150441
CY2016Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1534977
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2016Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet
CY2016Q2	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20434
CY2016Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21757
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-60417
CY2016Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-18515
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-43091
CY2016Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-12432
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-58172
CY2016Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	109122
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-3503
CY2016Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8400000
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7414375
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7840408
CY2017Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000
	us-gaap	Interest Expense Debt InterestExpenseDebt	9000
	us-gaap	Interest Expense Debt InterestExpenseDebt	253000
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1259
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-109
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7838
	us-gaap	Interest Paid Net InterestPaidNet	8140
CY2016Q2	us-gaap	Interest Paid Net InterestPaidNet
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	29600
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	18100
CY2017Q2	us-gaap	Inventory Net InventoryNet	89179
CY2016Q4	us-gaap	Inventory Net InventoryNet	69954
CY2017Q2	us-gaap	Licenses Revenue LicensesRevenue
CY2016Q2	us-gaap	Licenses Revenue LicensesRevenue
	us-gaap	Licenses Revenue LicensesRevenue
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	68800
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	59800
CY2017Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	9200
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	8000
	us-gaap	Inventory Write Down InventoryWriteDown	1209
CY2016Q2	us-gaap	Inventory Write Down InventoryWriteDown
CY2017Q2	us-gaap	Liabilities Liabilities	1930429
CY2016Q4	us-gaap	Liabilities Liabilities	1570726
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8839766
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14056753
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1850086
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1447292
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 15pt 0pt 18pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">– Description of Business and Bankruptcy Proceedings</div></div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 51pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Description of Business</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Nuo Therapeutics, Inc. (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing its products primarily within the U.S. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth opportunities for the Aurix System in the United States in the near to intermediate term include the treatment of chronic wounds with Aurix in: (i) the Medicare population under a National Coverage Determination (“NCD”), when registry data is collected under the Coverage with Evidence Development (“CED”)<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> program of the Centers for Medicare & Medicaid Services (“CMS”); and (ii) the Veterans Affairs (“VA”) healthcare system and other federal accounts settings. </div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> our commercial offering consists solely of the Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet based therapy for the chronic wound care market. Prior to the Effective Date (as defined below), we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> distinct platelet rich plasma (“PRP”) devices: the Aurix System for wound care, and the Angel® concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Prior to the Effective Date, Arthrex, Inc. (“Arthrex”) was our exclusive distributor for Angel. Pursuant to the Plan of Reorganization (as defined below), on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016, </div>the Company assigned its rights, title and interest in and to its existing license agreement with Arthrex to Deerfield (as defined below), as well as rights to collect royalty payments thereunder.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Bankruptcy Proceedings</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 26, 2016, </div>the Company filed a voluntary petition in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of Title <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of the United States Code (the “Bankruptcy Code”), which is administered under the caption “In re: Nuo Therapeutics, Inc.”, Case <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10192</div> (MFW) (the “Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> Case”).</div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 25, 2016</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> (the “Confirmation Date”), the Bankruptcy Court entered an Order Granting Final Approval of Disclosure Statement and Confirming Debtor’s Plan of Reorganization (the “Confirmation Order”), which confirmed the Modified First Amended Plan of Reorganization of the Debtor under Chapter <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> of the Bankruptcy Code (as confirmed, the “Plan,” or “Plan of Reorganization”).</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Scenario A<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"> contemplated by the Plan of Reorganization became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016 (</div>the “Effective Date”). Pursuant to the Plan, as of the Effective Date: (i) all equity interests of the Company, including but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to all shares of the Company’s common stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> par value per share (including its redeemable common stock) (the “Old Common Stock”), warrants, and options that were issuable or issued and outstanding immediately prior to the Effective Date, were cancelled; (ii) the Company’s certificate of incorporation that was in effect immediately prior to the Effective Date was amended and restated in its entirety; (iii) the Company’s by-laws that were in effect immediately prior to the Effective Date were amended and restated in their entirety; and (iv) the Company issued New Common Stock, Warrants and Series A Preferred Stock (all as defined below).</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Upon emergence from bankruptcy on the Effective Date, the Company applied fresh start accounting, resulting in the Company becoming a new entity for financial reporting purposes (see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">– <div style="display: inline; font-style: italic;">Fresh Start Accounting</div>). As a result of the application of fresh start accounting, the Company reflected the disposition of its pre-petition debt and changes in its equity structure effected under the Confirmation Order in its balance sheet as of the Effective Date. Accordingly, all financial statements prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016 </div>are referred to as those of the "Predecessor Company", as they reflect the periods prior to application of fresh start accounting. The financial statements for periods subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 4, 2016, </div>are referred to as those of the "Successor Company." Under fresh start accounting, the Company's assets and liabilities were adjusted to their fair values, and a reorganization value for the entity was determined by the Company based upon the estimated fair value of the enterprise before considering values allocated to debt to be settled in the reorganization. The fresh start adjustments are material and affect the Company’s results of operations from and after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016. </div>As a result of the application of fresh start accounting and the effects of the implementation of the Plan of Reorganization, the financial statements on or after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> comparable to the financial statements prior to that date.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Common Stock</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Recapitalization</div></div> <div style=" margin: 0pt 7.5pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">In accordance with the Plan of Reorganization, as of the Effective Date, the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,500,000</div> shares (the “Recapitalization Shares”) of new common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> per share (the “New Common Stock”), to certain accredited investors (the “Recapitalization Investors”) for gross cash proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,300,000</div> and net cash to the Company of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,052,500</div> (the “Recapitalization Financing”).<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">200,000</div> of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,500,000</div> shares of New Common Stock were issued in partial payment of an advisory fee.  The net cash amount excludes the effect of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$100,000</div> in offering expenses paid from the proceeds of the DIP Financing (as defined below in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> - <div style="display: inline; font-style: italic;">Debt</div>), which was converted into Series A Preferred Stock as of the Effective Date, as described below under <div style="display: inline; font-style: italic;">“Series A Preferred Stock</div>.” As part of the Recapitalization Financing, the Company also issued warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,180,000</div> shares of New Common Stock to certain of the Recapitalization Investors (the “Warrants”). The Warrants terminate on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">May 5, 2021</div>, </div>and are exercisable at any time on or after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">November 5, 2016</div> </div>at exercise prices ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.50</div> per share to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share.  The number of shares of New Common Stock underlying a Warrant and its exercise price are subject to customary adjustments upon subdivisions, combinations, payment of stock dividends, reclassifications, reorganizations and consolidations. A significant majority of the Recapitalization Investors executed backstop commitments to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,800,000</div> additional shares of New Common Stock for an aggregate purchase price of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3,000,000</div> (collectively, the “Backstop Commitment”). The Company could <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> call the Backstop Commitment prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">June 30, 2017</div> (</div>see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> - <div style="display: inline; font-style: italic;">Subsequent Event</div><div style="display: inline; font-style: italic;">s</div> for additional details).</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">With respect to each Recapitalization Investor who executed a Backstop Commitment, the commitment would have terminated on the earlier of: (i) the date on which the Company received net proceeds (after deducting all costs, expenses and commissions) from the sale of New Common Stock in the aggregate amount of the Backstop Commitment; (ii) the date that all shares of Series A Preferred Stock (as defined below) had been redeemed by the Company; or (iii) the date that all shares of Series A Preferred Stock were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer owned by entities affiliated with Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund II, L.P.<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">  (“Deerfield”). We refer to this date as the “Termination Date.” Under the terms of the Backstop Commitment, the Company would have been obligated to pay to the committed Recapitalization Investors a commitment fee of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> in the aggregate upon the Termination Date.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">As of the Effective Date, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Recapitalization Investors.<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">  The Registration Rights Agreement provides certain resale registration rights to the Recapitalization Investors with respect to securities received in the Recapitalization Financing.  Pursuant to the Registration Rights Agreement, the Company filed, and has to update periodically, a registration statement covering the resale of all shares of New Common Stock issued to the Recapitalization Investors on the Effective Date until such time as such shares have been sold or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be sold without registration or restriction pursuant to Rule <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">144</div> under the Securities Act. </div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Issuance of New Common Stock to Holders of Old Common Stock</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">As of the Effective Date, the Company committed to the issuance of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000,000</div> shares of New Common Stock and subsequently issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,264,612</div> shares of New Common Stock (the “Exchange Shares”) to record holders of the Old Common Stock as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2016, </div>who executed and timely delivered the required release documents <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> later than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 5, 2016, </div>in accordance with the Confirmation Order and the Plan.<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">  The holders of Old Common Stock who executed and timely delivered the required release documents are referred to as the “Releasing Holders.”</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,264,612</div> Exchange Shares were issued as of the Effective Date to Releasing Holders who asserted ownership of a number of shares of Old Common Stock that matched the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s records or could otherwise be confirmed at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of New Common Stock for every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41.8934</div> shares of Old Common Stock held by such holders as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 28, 2016.  </div>In accordance with the Plan, if the calculation would otherwise have resulted in the issuance to any Releasing Holder of a number of shares of New Common Stock that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> a whole number, then the number of shares actually issued to such Releasing Holder was determined by rounding down to the nearest number.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Issuance of Shares in Exchange for Administrative Claims</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2016, </div>the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,500</div> shares of New Common Stock (the “Administrative Claim Shares”) pursuant to the Order Granting Application of the Ad Hoc Equity Committee Pursuant to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> U.S.C. §§ <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)(D) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) for Allowance of Fees and Expenses Incurred in Making a Substantial Contribution, entered by the Bankruptcy Court on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2016.</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">   The Administrative Claim Shares were issued to holders of administrative claims under sections <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)(D) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">503</div>(b)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) of the Bankruptcy Code. Of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162,500</div> shares, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div> shares were issued to outside counsel to the Ad Hoc Equity Committee of the Company’s equity holders as compensation of all remaining allowed fees for legal services provided by such counsel.  The remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">62,500</div> were issued to designees of the Ad Hoc Equity Committee who had granted loans in an aggregate amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$62,500</div> to the Ad Hoc Equity Committee in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2015 </div>as repayment of such loans.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Series A Preferred Stock</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On the Effective Date, the Company filed a Certificate of Designations of Series A Preferred Stock (the “Certificate of Designations”) with the Delaware Secretary of State, designating <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,038</div> shares of the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s undesignated preferred stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.0001</div> per share, as Series A Preferred Stock (the “Series A Preferred Stock”). On the Effective Date, the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,038</div> shares of Series A Preferred Stock to Deerfield in accordance with the Plan pursuant to the exemption from the registration requirements of the Securities Act provided by Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1145</div> of the Bankruptcy Code. Deerfield did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> receive any shares of New Common Stock or other equity interests in the Company.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">   </div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt 7.5pt 0pt 18pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: justify;">The Series A Preferred Stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> stated maturity date, is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> convertible or redeemable, and carries a liquidation preference of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,038,000,</div> which is required to be paid to holders of such Series A Preferred Stock before any payments are made with respect to shares of New Common Stock (and other capital stock that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> issued on parity or senior to the Series A Preferred Stock) upon a liquidation or change in control transaction.<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">  For so long as Series A Preferred Stock is outstanding, the holders of Series A Preferred Stock have the right to nominate and elect <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> member of the board of directors of the Company (the “Board of Directors”) and to have such director serve on a standing committee of the Board of Directors established to exercise powers of the Board of Directors in respect of decisions or actions relating to the Backstop Commitment.   The holders of the Series A Preferred Stock nominated and elected <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> member of the Board of Directors to serve as the designee of the holders of Series A Preferred Stock. The Series A Preferred Stock has voting rights, voting with the New Common Stock as a single class, with each share of Series A Preferred Stock having the right to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div></div> votes, which currently represents approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> percent (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div>) of the voting rights of the capital stock of the Company.  The holders of Series A Preferred Stock have the right to approve certain transactions and incurrences of debt. The Certificate of Designations limits the Company’s ability to pay dividends on or purchase shares of its capital stock.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Assignment and Assumption Agreement; Transition Services Agreement</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the Plan, on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 5, 2016, </div>the Company entered into an Assignment and Assumption Agreement with Deerfield SS, LLC (the “Assignee”), the designee of Deerfield, to assign to the Assignee the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">’s rights, title and interest in and to its existing license agreement with Arthrex, and to transfer and assign to the Assignee associated intellectual property owned by the Company and licensed thereunder, as well as rights to collect royalty payments thereunder. The assignment and transfer was effected in exchange for a reduction of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000,000</div> in the amount of the allowed claim of Deerfield pursuant to the Plan. As a result of the assignment and transfer, the Aurix System currently represents the Company’s only commercial product offering.</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Termination of Deerfield Facility Agreement and DIP Credit Agreement</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">On the Effective Date, the obligations of the Company under the Deerfield Facility Agreement, and under the DIP Credit Agreement (as defined below in Note <div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> - <div style="display: inline; font-style: italic;">Debt</div>), were cancelled in accordance with the Plan of Reorganization, and the Company ceased to have any obligations thereunder.</div></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
CY2016Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	5417
CY2016Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2294406
CY2016Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4291218
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-3912061
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-1294843
	us-gaap	Net Income Loss NetIncomeLoss	-5604661
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5604661
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5604661
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1240
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-189387
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8969
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	3822050
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	1064500
	us-gaap	Operating Expenses OperatingExpenses	5409577
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3910821
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1105456
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5595692
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	218313
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	278730
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80343
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	123434
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20124
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1131
CY2016Q2	us-gaap	Postconfirmation Additional Paid In Capital PostconfirmationAdditionalPaidInCapital	17887966
CY2016Q2	us-gaap	Postconfirmation Amortizable Intangible Assets PostconfirmationAmortizableIntangibleAssets	8397000
CY2016Q2	us-gaap	Postconfirmation Amortizable Intangible Assets PostconfirmationAmortizableIntangibleAssets	8397000
CY2016Q2	us-gaap	Postconfirmation Assets PostconfirmationAssets	24049746
CY2016Q2	us-gaap	Postconfirmation Cash And Cash Equivalents PostconfirmationCashAndCashEquivalents	10358209
CY2016Q2	us-gaap	Postconfirmation Common Stock PostconfirmationCommonStock	750
CY2016Q2	us-gaap	Postconfirmation Current Assets PostconfirmationCurrentAssets	12352005
CY2016Q2	us-gaap	Postconfirmation Goodwill PostconfirmationGoodwill	2079000
CY2016Q2	us-gaap	Postconfirmation Goodwill PostconfirmationGoodwill	2079284
CY2016Q2	us-gaap	Postconfirmation Inventories PostconfirmationInventories	56348
CY2016Q2	us-gaap	Postconfirmation Liabilities PostconfirmationLiabilities	6161027
CY2016Q2	us-gaap	Postconfirmation Liabilities And Stockholders Equity PostconfirmationLiabilitiesAndStockholdersEquity	24049746
CY2016Q2	us-gaap	Postconfirmation Liabilities Subject To Compromise PostconfirmationLiabilitiesSubjectToCompromise
CY2016Q2	us-gaap	Postconfirmation Preferred Stock PostconfirmationPreferredStock	3
CY2016Q2	us-gaap	Postconfirmation Prepaid And Other Current Assets PostconfirmationPrepaidAndOtherCurrentAssets	595540
CY2016Q2	us-gaap	Postconfirmation Property And Equipment Net PostconfirmationPropertyAndEquipmentNet	865716
CY2016Q2	us-gaap	Postconfirmation Receivables Net PostconfirmationReceivablesNet	1288445
CY2016Q2	us-gaap	Postconfirmation Restricted Cash And Cash Equivalents Current PostconfirmationRestrictedCashAndCashEquivalentsCurrent	53463
CY2016Q2	us-gaap	Postconfirmation Retained Earnings Deficit PostconfirmationRetainedEarningsDeficit
CY2016Q2	us-gaap	Postconfirmation Stockholders Equity PostconfirmationStockholdersEquity	17888719
CY2016Q2	us-gaap	Preconfirmation Additional Paid In Capital PreconfirmationAdditionalPaidInCapital	126011808
CY2016Q2	us-gaap	Preconfirmation Amortizable Intangible Assets Net PreconfirmationAmortizableIntangibleAssetsNet	2406457
CY2016Q2	us-gaap	Preconfirmation Assets PreconfirmationAssets	8943472
CY2016Q2	us-gaap	Preconfirmation Cash And Cash Equivalents PreconfirmationCashAndCashEquivalents	3305709
CY2016Q2	us-gaap	Preconfirmation Common Stock PreconfirmationCommonStock	12477
CY2016Q2	us-gaap	Preconfirmation Current Assets PreconfirmationCurrentAssets	5315558
CY2016Q2	us-gaap	Preconfirmation Goodwill PreconfirmationGoodwill	0
CY2016Q2	us-gaap	Preconfirmation Inventories PreconfirmationInventories	56348
CY2016Q2	us-gaap	Preconfirmation Liabilities PreconfirmationLiabilities	51900824
CY2016Q2	us-gaap	Preconfirmation Liabilities And Stockholders Equity PreconfirmationLiabilitiesAndStockholdersEquity	8943472
CY2016Q2	us-gaap	Preconfirmation Liabilities Subject To Compromise PreconfirmationLiabilitiesSubjectToCompromise	39089877
CY2016Q2	us-gaap	Preconfirmation Preferred Stock PreconfirmationPreferredStock	0
CY2016Q2	us-gaap	Preconfirmation Prepaid And Other Current Assets PreconfirmationPrepaidAndOtherCurrentAssets	611593
CY2016Q2	us-gaap	Preconfirmation Property And Equipment Net PreconfirmationPropertyAndEquipmentNet	865716
CY2016Q2	us-gaap	Preconfirmation Receivables Net PreconfirmationReceivablesNet	1288445
CY2016Q2	us-gaap	Preconfirmation Restricted Cash And Cash Equivalents Current PreconfirmationRestrictedCashAndCashEquivalentsCurrent	53463
CY2016Q2	us-gaap	Preconfirmation Retained Earnings Deficit PreconfirmationRetainedEarningsDeficit	-169874587
CY2016Q2	us-gaap	Preconfirmation Stockholders Equity PreconfirmationStockholdersEquity	-43457352
CY2017Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000
CY2016Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	29038000
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29038
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29038
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	3
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	3
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	276265
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	334437
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt
CY2016Q2	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt
	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	1914
CY2016Q2	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	762855
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	765717
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	307093
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	486116
CY2016Q2	us-gaap	Reorganization Items ReorganizationItems	209402
CY2017Q2	us-gaap	Reorganization Items ReorganizationItems
	us-gaap	Reorganization Items ReorganizationItems
CY2016Q2	us-gaap	Reorganization Value ReorganizationValue	24050000
CY2016Q2	us-gaap	Reorganization Value ReorganizationValue	24050000
CY2017Q2	us-gaap	Reorganization Value Present Value Of Discounted Cash Flows Of Emerging Entity ReorganizationValuePresentValueOfDiscountedCashFlowsOfEmergingEntity
CY2016Q2	us-gaap	Reorganization Value Present Value Of Discounted Cash Flows Of Emerging Entity ReorganizationValuePresentValueOfDiscountedCashFlowsOfEmergingEntity	1054426
CY2016Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	201200
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	309486
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	224369
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	708900
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	53503
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11300288
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5695627
CY2017Q2	us-gaap	Revenues Revenues	188600
CY2016Q2	us-gaap	Revenues Revenues	134857
	us-gaap	Revenues Revenues	361343
CY2017Q2	us-gaap	Royalty Revenue RoyaltyRevenue	40885
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	25967
	us-gaap	Royalty Revenue RoyaltyRevenue	100546
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	147715
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	108890
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	260797
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	160681
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	237314
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	374381
	us-gaap	Share Based Compensation ShareBasedCompensation	27971
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	12163
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83
	us-gaap	Stock Issued1 StockIssued1
CY2016Q2	us-gaap	Stock Issued1 StockIssued1	217936
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	6909337
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	12486027
CY2017Q2	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	50000
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
CY2016Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt 51pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" margin: 0pt 15pt 0pt 18pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying condensed consolidated financial statements, estimates are used for, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, the application of fresh start accounting, stock-based compensation, allowance for inventory obsolescence, allowance for doubtful accounts, valuation of derivative liabilities, contingent liabilities, fair value and depreciable lives of long-lived assets (including property and equipment, intangible assets and goodwill), deferred taxes and associated valuation allowance and the classification of our long-term debt. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div>
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9927112
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9927112
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9793630
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9927112
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9927112
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9793630

Files In Submission

Name	View Source	Status
0001437749-17-014570-index-headers.html	Edgar Link	pending
0001437749-17-014570-index.html	Edgar Link	pending
0001437749-17-014570.txt	Edgar Link	pending
0001437749-17-014570-xbrl.zip	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nuot-20170630.xml	Edgar Link	completed
nuot-20170630.xsd	Edgar Link	pending
nuot-20170630_cal.xml	Edgar Link	unprocessable
nuot-20170630_def.xml	Edgar Link	unprocessable
nuot-20170630_lab.xml	Edgar Link	unprocessable
nuot-20170630_pre.xml	Edgar Link	unprocessable
nuot20170630_10q.htm	Edgar Link	pending
nuot20170630_10qimg001.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AURX
Nuo Therapeutics Inc Stock $aurx

2017 Q2 Form 10-Q Financial Statement

#000143774917014570 Filed on August 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX Nuo Therapeutics Inc Stock $aurx

2017 Q2 Form 10-Q Financial Statement

#000143774917014570 Filed on August 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AURX
Nuo Therapeutics Inc Stock $aurx